ERBB2 and cancer: Although monoclonal antibody-based therapeutics such as trastuzumab have revolutionized the management of HER2-positive cancers, the frequent occurrence of drug resistance and the intrinsic limitations in binding affinity and specificity underscore the pressing need for alternative therapeutic approaches [5].